top of page
  • Writer's pictureColliers | Columbus


Written by: Aaron Jodka

As Research Director | U.S. Capital Markets, Aaron is responsible for all aspects of research within the Capital Markets platform. He synthesizes and interprets a variety of data and information to stay ahead of trends that put our clients in an optimal position to make informed decisions. At the same time, he promotes the Colliers brand via best-in-class research reports, weekly insight posts, thought leadership, and contributions to numerous panels, media outlets, and industry events. With a deep understanding of markets throughout the country, he provides a unique perspective on market dynamics across asset types and investment strategies, providing clients with tailored data and analytics to ultimately guide decision-making solutions. Check out his post on Colliers Knowledge Leader here.

The life sciences market was not immune to macroeconomic trends in 2022. The rising cost of capital, slumping stock market, geopolitical tension, and decades-high inflation all weighed on the industry. General investor sentiment, across asset classes and industries, shifted to a risk-off mindset that clearly affected venture capital (VC) funding and the IPO market.

What hasn’t changed are the underlying fundamentals of the life sciences industry. As the U.S. population ages, there is an increasing need for medical care and discovery. And continued technological advancements are opening the door for customized or individualized care and treatment for patients. Meanwhile, the tremendous investment in the life sciences in recent years comes with a clear need for the talent so incredibly important to this industry.

Download the report.

14 views0 comments


bottom of page